Anti-CTLA-and anti-PD-1 immune checkpoint inhibitor antibodies impair human sperm motility in-vitro

Anti-CTLA-and anti-PD-1 immune checkpoint inhibitor antibodies impair human sperm motility in-vitro

BackgroundImmune checkpoint inhibitors (ICIs), namely, anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4) monoclonal antibody Ipilimumab and anti- and programmed cell death 1 (PD-1) monoclonal antibodies Nivolumab, and Pembrolizumab, have improved the treatment outcomes for many other cancer...

Full description

Saved in:
Bibliographic Details
Main Authors: Ilaria Cosci, Luca De Toni, Paolo Del Fiore, Andrea Di Nisio, Samuela Carraro, Claudia Maria Radu, Loris Bertazza, Simone Mocellin, Jacopo Pigozzo, Giovanna Crivellaro, Marina Coppola, Alberto Ferlin
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-03-01
Series:Frontiers in Pharmacology
Subjects:
ipilimumab
Nivolumab
Pembrolizumab
Annexin-V
TUNEL
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1534975/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1534975/full

Similar Items